Hepatocellular Carcinoma – Landscape & Forecast – Disease Landscape & Forecast
Hepatocellular carcinoma remains a challenging disease with a complex underlying etiology. While angiogenesis inhibitors including Nexavar (Bayer / Amgen), Stivarga (Bayer), Lenvima (Eisai / Merck & Co.), Cabometyx (Exelixis / Ipsen / Takeda), and Cyramza (Eli Lilly) have been central to the treatment of advanced disease, the market is set to witness a substantial change within the next 10 years driven by the 2020 approval of Tecentriq (Roche / Genentech) plus bevacizumab, the FDA approval of Imfinzi plus Imjudo (AstraZeneca) and the anticipated entry of novel emerging immune checkpoint inhibitor-based combinations. The anticipated uptake of these premium-priced regimens and their expected label expansion into the untapped early-stage setting will drive robust growth of the hepatocellular carcinoma market, where identified unmet needs remain to offer further opportunities for effective therapy development.
Questions answered
- What are the current therapies for hepatocellular carcinoma, and what are the main unmet needs?
- What is the size of market-relevant drug-treatable populations, and how will drug-treatment rates change over time?
- What is the expected market impact of recent and forecast drug approvals on the various subpopulations of hepatocellular carcinoma? What are interviewed experts’ insights on key existing and emerging agents?
- What are the key factors driving or constraining market growth?
Content highlights
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: 19 country-specific interviews with thought-leading medical oncologists.
Key companies: Bayer HealthCare / Amgen / Onyx, Bristol Myers Squibb / Ono Pharmaceutical, Merck & Co., Eisai, Exelixis / Ipsen, Eli Lilly, Roche / Genentech, AstraZeneca.
Key drugs: Nexavar, Lenvima, Stivarga, Cabometyx, Cyramza, Avastin, Tecentriq, Opdivo, Yervoy, Keytruda, Imfinzi, Imjudo.
Population segments in the market forecast: early-stage, first-line intermediate-stage, second-line intermediate-stage, first-line advanced-stage, and second-line advanced-stage hepatocellular carcinoma.
Emerging therapies: Phase III/PR: 4 drugs; coverage of select Phase I and Phase II products.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Hepatocellular Carcinoma - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Key updates
- April 2023
- January 2023
- Q4 2022
- December 2022
- Q3 2022
- August 2022
- Q2 2022
- June 2022
- May 2022
- April 2022
- Market outlook
- Key findings
- Market share of drug classes for hepatocellular carcinoma: 2021
- Market share of drug classes for hepatocellular carcinoma: 2031
- Drug-treatable population share and major-market sales share in hepatocellular carcinoma: 2021
- Drug-treatable population share and major-market sales share in hepatocellular carcinoma: 2031
- Current therapies with sales potential in hepatocellular carcinoma: population positioning
- Emerging therapies with sales potential in hepatocellular carcinoma: population positioning
- Hepatocellular carcinoma SWOT analysis
- Market drivers and constraints
- What factors are driving the market for hepatocellular carcinoma?
- What factors are constraining the market for hepatocellular carcinoma?
- Major-market sales for hepatocellular carcinoma by drug-treatable population: 2021-2031
- Major-market sales of immune checkpoint inhibitors for hepatocellular carcinoma: 2021-2031
- Major-market sales of angiogenesis inhibitors for hepatocellular Carcinoma: 2021-2031
- Segment-specific trends
- Patient-share dynamics of therapies for early-stage hepatocellular carcinoma in the United States: 2021-2031
- Patient-share dynamics of therapies in first-line intermediate-stage hepatocellular carcinoma in the United States: 2021-2031
- Patient-share dynamics of therapies in second-line intermediate-stage hepatocellular carcinoma in the United States: 2021-2031
- Patient-share dynamics of therapies in first-line advanced-stage hepatocellular carcinoma in the United States: 2021-2031
- Patient-share dynamics of therapies in second-line advanced-stage hepatocellular carcinoma in the United States: 2021-2031
- Key findings
- Forecast
- Market forecast downloads
- Market forecast assumptions
- Market forecast dashboard
- Etiology and pathophysiology
- Disease overview
- Etiology
- Key risk factors associated with the development of hepatocellular carcinoma
- Disease pathophysiology
- Liver anatomy and tumorigenesis
- Hepatocellular carcinoma pathogenesis
- Staging and classification
- Barcelona Clinic Liver Cancer staging criteria
- TNM-AJCC staging system
- TNM-LCSGJ staging system
- Child-Pugh score
- Key pathways and drug targets
- Drug targets and potential therapies for hepatocellular carcinoma
- Drug targets for hepatocellular carcinoma
- Biology of immune checkpoint inhibitors and modulators
- Disease overview
- Epidemiology
- Key findings
- Epidemiology populations
- Disease definition
- Methods
- Sources used for diagnosed incidence of hepatocellular carcinoma
- Diagnosed incident cases of hepatocellular carcinoma: 2021-2031
- Disease definition
- Methods
- Sources used for stage distribution of hepatocellular carcinoma
- Diagnosed incident cases of hepatocellular carcinoma by stage distribution: 2021-2031
- Definition
- Methods
- Sources used for recurrent incidence of hepatocellular carcinoma
- Recurrent incident cases of hepatocellular carcinoma: 2021-2031
- Hepatocellular carcinoma patient flow
- Drug-treatable cases: 2021-2031
- Drug-treated cases: 2021-2031
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for hepatocellular carcinoma
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for hepatocellular carcinoma
- Current treatments used for hepatocellular carcinoma
- Market events impacting the use of key current therapies for hepatocellular carcinoma
- Key results from select clinical trials investigating Nexavar for the treatment of hepatocellular carcinoma
- Ongoing clinical development of Nexavar
- Key ongoing clinical trials of Nexavar in the treatment of hepatocellular carcinoma
- Expert insight: sorafenib
- Key results from select clinical trials investigating Stivarga for the treatment of hepatocellular carcinoma
- Ongoing clinical development of Stivarga
- Key ongoing clinical trials of Stivarga in the treatment of hepatocellular carcinoma
- Expert insight: Stivarga
- Key results from select clinical trials investigating Lenvima for the treatment of hepatocellular carcinoma
- Ongoing clinical development of Lenvima
- Key ongoing clinical trials of Lenvima in the treatment of hepatocellular carcinoma
- Expert insight: Lenvima
- Key results from select clinical trials investigating Cabometyx for the treatment of hepatocellular carcinoma
- Ongoing clinical development of Cabometyx
- Key ongoing clinical trials of Cabometyx in the treatment of hepatocellular carcinoma
- Expert insight: Cabometyx
- Key results from select clinical trials investigating Cyramza for the treatment of hepatocellular carcinoma
- Ongoing clinical development program for Cyramza
- Expert insight: Cyramza
- Key results from select clinical trials investigating Opdivo (with or without Yervoy) for the treatment of hepatocellular carcinoma
- Ongoing clinical development of Opdivo (with or without Yervoy)
- Key ongoing clinical trials of Opdivo (with or without Yervoy) in the treatment of hepatocellular carcinoma
- Expert insight: Opdivo (with or without Yervoy)
- Key results from select clinical trials investigating Keytruda for the treatment of hepatocellular carcinoma
- Ongoing clinical development of Keytruda
- Key ongoing clinical trials of Keytruda in the treatment of hepatocellular carcinoma
- Expert insight: Keytruda
- Key results from select clinical trials investigating Tecentriq for the treatment of hepatocellular carcinoma
- Ongoing clinical development program for Tecentriq
- Key ongoing clinical trials of Tecentriq in the treatment of hepatocellular carcinoma
- Expert insight: Tecentriq
- Key results from select clinical trials investigating Imfinzi (with and without Imjudo) for the treatment of hepatocellular carcinoma
- Ongoing clinical development program for Imfinzi (with and without Imjudo)
- Key ongoing clinical trials of Imfinzi (with and without Imjudo) in the treatment of hepatocellular carcinoma
- Expert insight: Imfinzi (with and without Imjudo)
- Medical practice
- u200bEarly-stage hepatocellular carcinoma
- Intermediate-stage hepatocellular carcinoma
- Advanced-stage hepatocellular carcinoma
- Patient characteristics influencing drug selection in hepatocellular carcinoma
- Treatment decision tree for hepatocellular carcinoma: United States
- Treatment decision tree for hepatocellular carcinoma: Europe
- Treatment decision tree for hepatocellular carcinoma: Japan
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in hepatocellular carcinoma
- Top unmet needs in hepatocellular carcinoma: current and future attainment
- Expert insight: unmet need in hepatocellular carcinoma
- Drug Pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for hepatocellular carcinoma
- Estimated market authorization dates of key emerging therapies for the treatment of hepatocellular carcinoma
- Key results from select clinical trials investigating tislelizumab for the treatment of hepatocellular carcinoma
- Key ongoing clinical trials of tislelizumab in the treatment of hepatocellular carcinoma
- Analysis of the clinical development program for Tislelizumab
- Expert insight: tislelizumab
- Expectations for market authorization and sales opportunity of tislelizumab in hepatocellular carcinoma
- Key results from select clinical trials investigating camrelizumab plus rivoceranib for the treatment of hepatocellular carcinoma
- Key ongoing clinical trials of camrelizumab plus rivoceranib in the treatment of hepatocellular carcinoma
- Analysis of the clinical development program for camrelizumab plus rivoceranib
- Expert insight: camrelizumab plus rivoceranib
- Expectations for market authorization and sales opportunity of camrelizumab plus rivoceranib in hepatocellular carcinoma
- Key results from select clinical trials investigating nofazinlimab for the treatment of hepatocellular carcinoma
- Key ongoing clinical trials of nofazinlimab in the treatment of hepatocellular carcinoma
- Analysis of the clinical development program for nofazinlimab
- Expectations for market authorization and sales opportunity of nofazinlimab in hepatocellular carcinoma
- Key ongoing clinical trials of toripalimab in the treatment of hepatocellular carcinoma
- Analysis of the clinical development program for toripalimab
- Expectations for market authorization and sales opportunity of toripalimab in hepatocellular carcinoma
- Key results from select clinical trials investigating namodenoson for the treatment of hepatocellular carcinoma
- Analysis of the clinical development program for namodenoson
- Key ongoing clinical trials of namodenoson in the treatment of hepatocellular carcinoma
- Expectations for market authorization and sales opportunity of namodenoson in hepatocellular carcinoma
- Early-phase pipeline analysis
- Select compounds in early-phase development for hepatocellular carcinoma
- Key findings
- Access & reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in hepatocellular carcinoma: United States
- General reimbursement environment: United States
- Key market access considerations in hepatocellular carcinoma: EU5
- General reimbursement environment: EU5
- Key market access considerations in hepatocellular carcinoma: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Hepatocellular carcinoma bibliography
- Key findings
Laura Ramos Garcia, M.Sc., Ph.D., is an analyst on the Oncology team at Clarivate. During her training as a Ph.D., she gained in-depth knowledge in the field of cell death and inflammation. As a postdoctoral researcher, she worked on an emerging type of small molecule, PROTAC, that allows targeted protein degradation. She obtained her master of science degree in molecular medicine at Imperial College London and her doctorate in cancer biology at the Institute of Cancer Research (University of London).